GB0922143D0 - Biological materials and uses thereof - Google Patents
Biological materials and uses thereofInfo
- Publication number
- GB0922143D0 GB0922143D0 GBGB0922143.3A GB0922143A GB0922143D0 GB 0922143 D0 GB0922143 D0 GB 0922143D0 GB 0922143 A GB0922143 A GB 0922143A GB 0922143 D0 GB0922143 D0 GB 0922143D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- biological materials
- biological
- materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0922143A GB2476293A (en) | 2009-12-18 | 2009-12-18 | Therapeutic inhibition of ROR-1 |
ES10798728.1T ES2635316T3 (en) | 2009-12-18 | 2010-12-10 | Antibodies against ROR1 that can induce LLC cell death |
PCT/EP2010/007524 WO2011079902A2 (en) | 2009-12-18 | 2010-12-10 | Biological materials and uses thereof |
EP10798728.1A EP2513146B1 (en) | 2009-12-18 | 2010-12-10 | Antibodies against ror1 capable of inducing cell death of cll |
DK10798728.1T DK2513146T3 (en) | 2009-12-18 | 2010-12-10 | Antibodies against ROR1 capable of inducing cell death by CLL |
CN201080061963.2A CN102712695B (en) | 2009-12-18 | 2010-12-10 | Biological inhibitors of ROR1 capable of inducing cell death |
US13/516,925 US9150647B2 (en) | 2009-12-18 | 2010-12-10 | Biological inhibitors of ROR1 capable of inducing cell death |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0922143A GB2476293A (en) | 2009-12-18 | 2009-12-18 | Therapeutic inhibition of ROR-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0922143D0 true GB0922143D0 (en) | 2010-02-03 |
GB2476293A GB2476293A (en) | 2011-06-22 |
Family
ID=41717185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0922143A Withdrawn GB2476293A (en) | 2009-12-18 | 2009-12-18 | Therapeutic inhibition of ROR-1 |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2476293A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002087618A1 (en) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Preventive/therapeutic method for cancer |
WO2007051077A2 (en) * | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
WO2008103849A2 (en) * | 2007-02-21 | 2008-08-28 | The Regents Of The University Of California | Methods and compounds for lymphoma cell detection and isolation |
WO2007146957A2 (en) * | 2006-06-13 | 2007-12-21 | Irm Llc | Ror1 as a therapeutic target for lung cancer |
WO2008076868A2 (en) * | 2006-12-18 | 2008-06-26 | Abbott Laboratories | Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1) |
WO2010008069A1 (en) * | 2008-07-18 | 2010-01-21 | 国立大学法人名古屋大学 | Cell proliferation inhibitor |
-
2009
- 2009-12-18 GB GB0922143A patent/GB2476293A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB2476293A (en) | 2011-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201107486B (en) | Anti-tnf-x antibodies and their uses | |
PT3222617T (en) | Psma-targeting compounds and uses thereof | |
EP2515822A4 (en) | Single-use containers and uses thereof | |
EP2494062A4 (en) | Anti-glp-1r antibodies and their uses | |
GB201011771D0 (en) | Biological material and particular uses thereof | |
HK1150614A1 (en) | Biological materials and uses thereof | |
EP2437052A4 (en) | Biosensor and usage thereof | |
HK1199888A1 (en) | Biological materials and uses thereof | |
IL215291A0 (en) | NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF | |
GB0904825D0 (en) | Biological materials and uses thereof | |
IL220536A0 (en) | Anti - bv8 antibodies and uses thereof | |
GB201002082D0 (en) | Biological material | |
IL214527A0 (en) | Anti-mst1r antibodies and uses thereof | |
GB0909768D0 (en) | Novel compounds and uses thereof | |
GB0701062D0 (en) | Biological materials and uses thereof | |
SI2246181T1 (en) | Compound material and its use | |
GB0811362D0 (en) | Biological materials and uses thereof | |
GB0922143D0 (en) | Biological materials and uses thereof | |
GB0802980D0 (en) | Biological materials and uses thereof | |
GB0906115D0 (en) | Antibody and uses thereof | |
GB0808956D0 (en) | biological materials and uses thereof | |
GB0802075D0 (en) | Biological materials and uses thereof | |
GB201009307D0 (en) | Biological materials and uses thereof | |
GB201011770D0 (en) | Biological material and there uses thereof | |
GB0711926D0 (en) | Biological materials and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |